PL3008039T3 - Krystaliczna postać inhibitora mdm2 - Google Patents

Krystaliczna postać inhibitora mdm2

Info

Publication number: PL3008039T3
Authority: PL; Poland
Prior art keywords: crystal form; mdm2 inhibitor; mdm2; inhibitor; crystal
Prior art date: 2013-06-10

Application number

PL14735785T

Other languages

English (en)

Inventor

Matthew Bio

Sebastien Caille

Brian Cochran

Yuanqing Fang

Brian M. Fox

Brian S. Lucas

Lawrence R. Mcgee

Filisaty VOUNATSOS

Sean WIEDEMANN

Sarah WORTMAN

Original Assignee

Amgen Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-06-10

Filing date

2014-06-09

Publication date

2021-04-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3008039(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-06-09 Application filed by Amgen Inc. filed Critical Amgen Inc.

2021-04-19 Publication of PL3008039T3 publication Critical patent/PL3008039T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C313/02—Sulfinic acids; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Enzymes And Modification Thereof (AREA)
Epoxy Compounds (AREA)

PL14735785T 2013-06-10 2014-06-09 Krystaliczna postać inhibitora mdm2 PL3008039T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361833196P	2013-06-10	2013-06-10
EP14735785.9A EP3008039B1 (en)	2013-06-10	2014-06-09	Crystalline form of a mdm2 inhibitor
PCT/US2014/041594 WO2014200937A1 (en)	2013-06-10	2014-06-09	Processes of making and crystalline forms of a mdm2 inhibitor

Publications (1)

Publication Number	Publication Date
PL3008039T3 true PL3008039T3 (pl)	2021-04-19

Family

ID=51063849

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14735785T PL3008039T3 (pl)	2013-06-10	2014-06-09	Krystaliczna postać inhibitora mdm2

Country Status (38)

Country	Link
US (10)	US9376386B2 (pl)
EP (2)	EP3008039B1 (pl)
JP (4)	JP6998655B2 (pl)
KR (4)	KR20160018576A (pl)
CN (3)	CN105358530A (pl)
AP (1)	AP2015008891A0 (pl)
AR (2)	AR096582A1 (pl)
AU (5)	AU2014278428B2 (pl)
BR (2)	BR122020003153B1 (pl)
CA (4)	CA3200532A1 (pl)
CL (3)	CL2015003589A1 (pl)
CR (2)	CR20210290A (pl)
CY (1)	CY1123661T1 (pl)
DK (1)	DK3008039T3 (pl)
EA (3)	EA031254B1 (pl)
ES (1)	ES2851023T3 (pl)
HR (1)	HRP20202065T1 (pl)
HU (1)	HUE053047T2 (pl)
IL (4)	IL297860A (pl)
JO (2)	JOP20200296A1 (pl)
LT (1)	LT3008039T (pl)
MA (3)	MA38714A1 (pl)
MX (2)	MX2015016856A (pl)
MY (2)	MY205257A (pl)
NZ (1)	NZ714821A (pl)
PE (2)	PE20210153A1 (pl)
PH (2)	PH12020550916A1 (pl)
PL (1)	PL3008039T3 (pl)
PT (1)	PT3008039T (pl)
RS (1)	RS61192B1 (pl)
SG (2)	SG10201801402XA (pl)
SI (1)	SI3008039T1 (pl)
SM (1)	SMT202100013T1 (pl)
TN (1)	TN2015000521A1 (pl)
TW (3)	TWI698428B (pl)
UA (1)	UA121301C2 (pl)
UY (1)	UY35605A (pl)
WO (1)	WO2014200937A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO2998B1 (ar)	2010-06-04	2016-09-05	Amgen Inc	مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
MX352672B (es)	2011-09-27	2017-12-04	Amgen Inc	Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
US11407721B2 (en)	2013-02-19	2022-08-09	Amgen Inc.	CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
WO2014151863A1 (en)	2013-03-14	2014-09-25	Amgen Inc.	Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) *	2013-06-10	2017-06-16	Amgen Inc	عمليات صنع وأشكال بلورية من mdm2 مثبط
CA2930244A1 (en)	2013-11-11	2015-05-14	Amgen Inc.	Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
ES2858151T3 (es)	2016-05-20	2021-09-29	Hoffmann La Roche	Conjugados de PROTAC-anticuerpo y procedimientos de uso
IL308399B1 (en) *	2018-04-30	2025-04-01	Kartos Therapeutics Inc	Cancer treatment methods
WO2019224803A2 (en) *	2018-05-25	2019-11-28	Kartos Therapeutics, Inc.	Methods of treating myeloproliferative neoplasms
JP7408635B2 (ja)	2018-08-31	2024-01-05	アムジエン・インコーポレーテツド	Ｍｄｍ２阻害剤を調製する方法
CN110963958A (zh) *	2018-09-30	2020-04-07	上海长森药业有限公司	一种mdm2抑制剂，及其制备方法、药物组合物和应用
GB201919219D0 (en)	2019-12-23	2020-02-05	Otsuka Pharma Co Ltd	Cancer biomarkers
US20230272001A1 (en) *	2020-05-22	2023-08-31	Merck Sharp & Dohme Llc	Novel processes for preparing conjugates of the il-2 protein
EP4204812A2 (en)	2020-08-27	2023-07-05	Otsuka Pharmaceutical Co., Ltd.	Biomarkers for cancer therapy using mdm2 antagonists
GB202103080D0 (en)	2021-03-04	2021-04-21	Otsuka Pharma Co Ltd	Cancer biomarkers
CA3227793A1 (en) *	2021-08-05	2023-02-09	Yong Moon Choi	Phenylcarbamate crystalline form and method for manufacturing the same
US12054449B2 (en)	2021-08-05	2024-08-06	Bio-Pharm Solutions Co., Ltd.	Phenylcarbamate crystalline form and method for manufacturing the same
WO2023039161A1 (en) *	2021-09-09	2023-03-16	Kartos Therapeutics	Methods of treating cancer dependent on myc gene expresssion
WO2023056069A1 (en)	2021-09-30	2023-04-06	Angiex, Inc.	Degrader-antibody conjugates and methods of using same
CN115925589A (zh) *	2022-12-26	2023-04-07	诚达药业股份有限公司	一种脂肪族亚磺酸钙盐及其制备方法
WO2024240858A1 (en)	2023-05-23	2024-11-28	Valerio Therapeutics	Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2483213A (en) *	1947-06-14	1949-09-27	American Cyanamid Co	Alpha naphthalene sulfonic anhydride
CH436295A (de)	1961-11-13	1967-05-31	Mcneilab Inc	Verfahren zur Herstellung neuer 3-Morpholinone
US3518236A (en) *	1967-07-20	1970-06-30	Uniroyal Inc	Acceleration of sulfur-vulcanization of rubber with sulfinic acids and derivatives
DE3246148A1 (de)	1982-12-14	1984-06-14	Troponwerke GmbH & Co KG, 5000 Köln	Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP2604472B2 (ja)	1989-07-12	1997-04-30	株式会社クラレ	重合性組成物
WO1995023135A1 (en)	1991-03-07	1995-08-31	Fisons Corporation	Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity
US5334720A (en)	1991-03-07	1994-08-02	Fisons Corporation	Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
ATE219077T1 (de)	1994-08-19	2002-06-15	Abbott Lab	Endothelin antagoniste
KR100508200B1 (ko)	1996-02-13	2005-12-16	아보트 러보러터리즈	엔도텔린길항제로서의벤조-1,3-디옥솔릴-및벤조푸라닐치환된피롤리딘유도체및이를함유하는약제
US6159990A (en)	1997-06-18	2000-12-12	Synaptic Pharmaceutical Corporation	Oxazolidinones as α1A receptor antagonists
TR200101234T2 (tr)	1997-08-04	2002-06-21	Abbott Laboratories	Endotelin antagonistleri.
AU1910299A (en)	1997-12-18	1999-07-05	Eli Lilly And Company	Peptidomimetic template-based combinatorial libraries
US6770658B2 (en)	1998-09-09	2004-08-03	Inflazyme Pharmaceuticals Ltd.	Substituted γ-phenyl-Δ-lactams and uses related thereto
US7214540B2 (en) *	1999-04-06	2007-05-08	Uab Research Foundation	Method for screening crystallization conditions in solution crystal growth
US6630006B2 (en) *	1999-06-18	2003-10-07	The Regents Of The University Of California	Method for screening microcrystallizations for crystal formation
US7052545B2 (en) *	2001-04-06	2006-05-30	California Institute Of Technology	High throughput screening of crystallization of materials
US7195670B2 (en) *	2000-06-27	2007-03-27	California Institute Of Technology	High throughput screening of crystallization of materials
DE19951418A1 (de) *	1999-10-26	2001-05-03	Merck Patent Gmbh	Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid
WO2002017912A1 (en)	2000-08-31	2002-03-07	Abbott Laboratories	Endothelin antagonists
US7229500B2 (en) *	2000-11-20	2007-06-12	Parallel Synthesis Technologies, Inc.	Methods and devices for high throughput crystallization
WO2002060894A2 (en)	2001-01-30	2002-08-08	Bristol-Myers Squibb Company	Sulfonamide lactam inhibitors of factor xa
CA2446380A1 (en)	2001-05-08	2002-11-14	Yale University	Proteomimetic compounds and methods
WO2002094787A1 (en)	2001-05-23	2002-11-28	Ucb, S.A.	2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
ES2301717T3 (es)	2001-12-18	2008-07-01	F. Hoffmann-La Roche Ag	Cis-2,4,5-trifenil-imidazolinas y su utilizacion para el tratamiento de tumores.
US6860940B2 (en) *	2002-02-11	2005-03-01	The Regents Of The University Of California	Automated macromolecular crystallization screening
US6916833B2 (en) *	2003-03-13	2005-07-12	Hoffmann-La Roche Inc.	Substituted piperidines
US7425638B2 (en)	2003-06-17	2008-09-16	Hoffmann-La Roche Inc.	Cis-imidazolines
ES2314660T3 (es)	2004-05-18	2009-03-16	F. Hoffmann-La Roche Ag	Nuevas cis-imidazolinas.
US7893278B2 (en)	2004-06-17	2011-02-22	Hoffman-La Roche Inc.	CIS-imidazolines
JP2007297283A (ja)	2004-07-28	2007-11-15	Santen Pharmaceut Co Ltd	新規桂皮酸関連化合物
WO2006044860A2 (en)	2004-10-18	2006-04-27	Amgen, Inc.	Thiadiazole compounds and methods of use
AU2006215041B2 (en)	2005-02-18	2012-05-31	Mitsubishi Tanabe Pharma Corporation	Salt of proline derivative, solvate thereof, and production method thereof
JP4955646B2 (ja)	2005-03-16	2012-06-20	エフ．ホフマン−ラロシュアーゲー	シス−２，４，５−トリアリール−イミダゾリン及びそれらの抗癌薬としての使用
US20060270709A1 (en)	2005-04-04	2006-11-30	Eisai Co. Ltd.	Dihydropyridine compounds and compositions for headaches
WO2006131923A2 (en)	2005-06-07	2006-12-14	Ramot At Tel Aviv University Ltd.	Novel salts of conjugated psychotropic drugs and processes of preparing same
WO2007015929A2 (en)	2005-07-27	2007-02-08	University Of Toledo	Epothilone analogues
EP1960368B1 (en)	2005-12-01	2015-05-06	F. Hoffmann-La Roche AG	2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents
WO2007084391A2 (en)	2006-01-18	2007-07-26	Amgen Inc.	Thiazole compounds as protein kinase b ( pkb) inhibitors
US20070213341A1 (en)	2006-03-13	2007-09-13	Li Chen	Spiroindolinone derivatives
KR20090042779A (ko)	2006-06-30	2009-04-30	쉐링 코포레이션	Ｐ53 활성을 증가시키는 치환된 피페리딘 및 이의 사용
EP2046328A4 (en)	2006-07-19	2009-10-28	Univ Georgia Res Found	PYRIDINONE DIKETOIC ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY
US20080045560A1 (en)	2006-08-15	2008-02-21	Wyeth	Pyrrolidine and related derivatives useful as PR modulators
WO2008021338A2 (en)	2006-08-15	2008-02-21	Wyeth	Tricyclic oxazolidone derivatives useful as pr modulators
TW200831080A (en)	2006-12-15	2008-08-01	Irm Llc	Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
GB0722769D0 (en)	2007-11-21	2008-01-02	Biolipox Ab	New compounds
JP2010522177A (ja)	2007-03-23	2010-07-01	アムジエン・インコーポレーテツド	複素環化合物およびその使用
EP2139882B1 (en)	2007-03-23	2013-12-25	Amgen Inc.	3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
SI2137186T1 (sl)	2007-03-23	2016-04-29	Amgen Inc.	Heterociklične spojine in njihove uporabe
US7625895B2 (en)	2007-04-12	2009-12-01	Hoffmann-Le Roche Inc.	Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (en)	2007-04-20	2008-10-30	University Of Pittsburg-Of The Commonwealth System Of Higher Education	Selective and dual-action p53/mdm2/mdm4 antagonists
US7834179B2 (en)	2007-05-23	2010-11-16	Hoffmann-La Roche Inc.	Spiroindolinone derivatives
WO2009004430A1 (en)	2007-06-29	2009-01-08	Pfizer Inc.	N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
US8138183B2 (en)	2007-07-09	2012-03-20	Astrazeneca Ab	Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
WO2009011880A2 (en)	2007-07-17	2009-01-22	Amgen Inc.	Heterocyclic modulators of pkb
CA2693473A1 (en)	2007-07-17	2009-01-22	Amgen Inc.	Thiadiazole modulators of pkb
PE20091008A1 (es)	2007-08-02	2009-08-10	Amgen Inc	Derivados heterociclicos como moduladores de fosfoinositida 3-cinasa
BRPI0817850A2 (pt)	2007-10-09	2015-04-07	Hoffmann La Rouche Ag F	Cis-imidazolinas quirais
US7776875B2 (en)	2007-12-19	2010-08-17	Hoffman-La Roche Inc.	Spiroindolinone derivatives
JP5520831B2 (ja)	2007-12-19	2014-06-11	アムジエン・インコーポレーテツド	Ｐｉ３キナーゼの阻害薬
EP2222296A2 (en)	2007-12-26	2010-09-01	Eisai R&D Management Co., Ltd.	Ampa receptor antagonists and zonisamide for epilepsy
WO2009114950A1 (en)	2008-03-21	2009-09-24	Chlorion Pharma, Inc.	Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain
EP2307400B1 (en)	2008-05-30	2014-04-23	Amgen, Inc	Inhibitors of pi3 kinase
GB0811643D0 (en)	2008-06-25	2008-07-30	Cancer Rec Tech Ltd	New therapeutic agents
WO2010030704A2 (en)	2008-09-10	2010-03-18	Achaogen, Inc.	Antibacterial aminoglycoside analogs
TW201011009A (en)	2008-09-15	2010-03-16	Priaxon Ag	Novel pyrrolidin-2-ones
CN102159207B (zh)	2008-09-18	2015-02-04	霍夫曼-拉罗奇有限公司	取代的吡咯烷-2-甲酰胺类
WO2010083246A1 (en)	2009-01-15	2010-07-22	Amgen Inc.	Fluoroisoquinoline substituted thiazole compounds and methods of use
WO2010096314A1 (en)	2009-02-18	2010-08-26	Amgen Inc.	INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS
EP2408773A2 (en)	2009-03-20	2012-01-25	Amgen, Inc	Inhibitors of pi3 kinase
US8076482B2 (en)	2009-04-23	2011-12-13	Hoffmann-La Roche Inc.	3,3′-spiroindolinone derivatives
UY32582A (es)	2009-04-28	2010-11-30	Amgen Inc	Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP2012526836A (ja)	2009-05-13	2012-11-01	アムジエン・インコーポレーテツド	Ｐｉｋｋ阻害薬としてのヘテロアリール化合物
EP2445898A2 (en)	2009-06-25	2012-05-02	Amgen, Inc	4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors
US20100331306A1 (en)	2009-06-25	2010-12-30	Amgen Inc.	Heterocyclic compounds and their uses
BR112012000660A2 (pt)	2009-06-25	2016-11-16	Amgen Inc	compostos heterociclos e seus usos
AU2010265971B2 (en)	2009-06-25	2014-08-14	Amgen Inc.	Heterocyclic compounds and their uses as inhibitors of PI3 K activity
MX2012002420A (es)	2009-08-26	2012-06-27	Novartis Ag	Compuestos de heteroarilo tetra-sustituidos y su uso como moduladores de mdm2 y/o mdm4.
JP2013507391A (ja)	2009-10-09	2013-03-04	アカオジェンインコーポレイテッド	抗ウイルスアミノグリコシド類似体
US8088815B2 (en)	2009-12-02	2012-01-03	Hoffman-La Roche Inc.	Spiroindolinone pyrrolidines
US8440693B2 (en)	2009-12-22	2013-05-14	Novartis Ag	Substituted isoquinolinones and quinazolinones
CN103843105A (zh) *	2010-02-10	2014-06-04	摩奇有限公司(d/b/aVoxa)	暗视野像差矫正电子显微镜
IT1399923B1 (it)	2010-05-11	2013-05-09	Cbb Net S A	Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono
JO2998B1 (ar)	2010-06-04	2016-09-05	Amgen Inc	مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
CA2824197C (en)	2011-01-10	2020-02-25	Michael Martin	Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN102153557B (zh)	2011-01-21	2013-03-20	中国科学院上海有机化学研究所	具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途
JP6025713B2 (ja) *	2011-04-28	2016-11-16	大塚化学株式会社	アゾジカルボンアミドの新規製造法
TW201309651A (zh)	2011-06-29	2013-03-01	Otsuka Pharma Co Ltd	阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
MX352672B (es)	2011-09-27	2017-12-04	Amgen Inc	Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
CN103373951B (zh) *	2012-04-28	2016-03-09	上海医药工业研究院	一种拉帕替尼中间体的制备方法
EP2958902B1 (en)	2013-02-19	2017-11-15	Amgen Inc.	Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
WO2014134201A1 (en)	2013-02-28	2014-09-04	Amgen Inc.	A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
WO2014151863A1 (en)	2013-03-14	2014-09-25	Amgen Inc.	Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar)	2013-06-10	2017-06-16	Amgen Inc	عمليات صنع وأشكال بلورية من mdm2 مثبط

2013
- 2013-06-10 JO JOP/2020/0296A patent/JOP20200296A1/ar unknown
2014
- 2014-06-09 PE PE2020000392A patent/PE20210153A1/es unknown
- 2014-06-09 KR KR1020157036194A patent/KR20160018576A/ko not_active Ceased
- 2014-06-09 LT LTEP14735785.9T patent/LT3008039T/lt unknown
- 2014-06-09 NZ NZ714821A patent/NZ714821A/en unknown
- 2014-06-09 MX MX2015016856A patent/MX2015016856A/es unknown
- 2014-06-09 KR KR1020217030265A patent/KR20210121270A/ko not_active Ceased
- 2014-06-09 AU AU2014278428A patent/AU2014278428B2/en active Active
- 2014-06-09 CA CA3200532A patent/CA3200532A1/en active Pending
- 2014-06-09 TN TN2015000521A patent/TN2015000521A1/en unknown
- 2014-06-09 CN CN201480033215.1A patent/CN105358530A/zh active Pending
- 2014-06-09 CA CA2914723A patent/CA2914723C/en active Active
- 2014-06-09 MX MX2019012007A patent/MX379872B/es unknown
- 2014-06-09 MA MA38714A patent/MA38714A1/fr unknown
- 2014-06-09 MY MYPI2019006678A patent/MY205257A/en unknown
- 2014-06-09 PH PH1/2020/550916A patent/PH12020550916A1/en unknown
- 2014-06-09 HU HUE14735785A patent/HUE053047T2/hu unknown
- 2014-06-09 AP AP2015008891A patent/AP2015008891A0/xx unknown
- 2014-06-09 EP EP14735785.9A patent/EP3008039B1/en active Active
- 2014-06-09 CN CN201811222652.4A patent/CN110003092A/zh active Pending
- 2014-06-09 MY MYPI2015002896A patent/MY194848A/en unknown
- 2014-06-09 IL IL297860A patent/IL297860A/en unknown
- 2014-06-09 EA EA201592305A patent/EA031254B1/ru unknown
- 2014-06-09 PT PT147357859T patent/PT3008039T/pt unknown
- 2014-06-09 KR KR1020247035781A patent/KR20240159641A/ko active Pending
- 2014-06-09 WO PCT/US2014/041594 patent/WO2014200937A1/en active Application Filing
- 2014-06-09 RS RS20201515A patent/RS61192B1/sr unknown
- 2014-06-09 SM SM20210013T patent/SMT202100013T1/it unknown
- 2014-06-09 BR BR122020003153-0A patent/BR122020003153B1/pt active IP Right Grant
- 2014-06-09 KR KR1020237002549A patent/KR20230019216A/ko not_active Ceased
- 2014-06-09 ES ES14735785T patent/ES2851023T3/es active Active
- 2014-06-09 CA CA3115609A patent/CA3115609C/en active Active
- 2014-06-09 CR CR20210290A patent/CR20210290A/es unknown
- 2014-06-09 CA CA3201958A patent/CA3201958A1/en active Pending
- 2014-06-09 EA EA201891642A patent/EA201891642A1/ru unknown
- 2014-06-09 EA EA202091612A patent/EA202091612A1/ru unknown
- 2014-06-09 UA UAA201600159A patent/UA121301C2/uk unknown
- 2014-06-09 DK DK14735785.9T patent/DK3008039T3/da active
- 2014-06-09 BR BR112015031004-4A patent/BR112015031004B1/pt active IP Right Grant
- 2014-06-09 PL PL14735785T patent/PL3008039T3/pl unknown
- 2014-06-09 PE PE2015002561A patent/PE20160113A1/es unknown
- 2014-06-09 SG SG10201801402XA patent/SG10201801402XA/en unknown
- 2014-06-09 JP JP2016519576A patent/JP6998655B2/ja active Active
- 2014-06-09 CN CN201910783352.1A patent/CN110627708A/zh active Pending
- 2014-06-09 MA MA53572A patent/MA53572A1/fr unknown
- 2014-06-09 SI SI201431735T patent/SI3008039T1/sl unknown
- 2014-06-09 SG SG11201509896VA patent/SG11201509896VA/en unknown
- 2014-06-09 EP EP20197741.0A patent/EP3805232A1/en active Pending
- 2014-06-10 UY UY0001035605A patent/UY35605A/es not_active Application Discontinuation
- 2014-06-10 TW TW107134691A patent/TWI698428B/zh active
- 2014-06-10 AR ARP140102235A patent/AR096582A1/es not_active Application Discontinuation
- 2014-06-10 TW TW109118829A patent/TWI791153B/zh active
- 2014-06-10 TW TW103120104A patent/TWI649306B/zh active
- 2014-06-10 US US14/301,087 patent/US9376386B2/en active Active
- 2014-06-10 JO JOP/2014/0186A patent/JO3768B1/ar active
2015
- 2015-11-16 IL IL242622A patent/IL242622B/en active IP Right Grant
- 2015-12-03 PH PH12015502705A patent/PH12015502705B1/en unknown
- 2015-12-10 CL CL2015003589A patent/CL2015003589A1/es unknown
- 2015-12-23 MA MA43288A patent/MA43288B1/fr unknown
2016
- 2016-01-07 CR CR20160010A patent/CR20160010A/es unknown
- 2016-05-24 US US15/163,186 patent/US9855259B2/en active Active
- 2016-06-07 US US15/175,824 patent/US9801867B2/en active Active
- 2016-06-07 US US15/175,798 patent/US20160287570A1/en not_active Abandoned
- 2016-06-07 US US15/175,805 patent/US9623018B2/en active Active
- 2016-06-07 US US15/175,821 patent/US9757367B2/en active Active
2017
- 2017-11-22 US US15/820,830 patent/US20180092898A1/en not_active Abandoned
2018
- 2018-11-07 AU AU2018260844A patent/AU2018260844B2/en active Active
2019
- 2019-01-08 CL CL2019000056A patent/CL2019000056A1/es unknown
- 2019-05-07 IL IL266504A patent/IL266504B/en active IP Right Grant
- 2019-10-25 US US16/664,103 patent/US20200281912A1/en not_active Abandoned
2020
- 2020-04-28 AR ARP200101191A patent/AR119727A2/es unknown
- 2020-05-14 JP JP2020084989A patent/JP6891322B2/ja active Active
- 2020-11-10 AU AU2020267169A patent/AU2020267169B2/en active Active
- 2020-12-18 CY CY20201101201T patent/CY1123661T1/el unknown
- 2020-12-24 HR HRP20202065TT patent/HRP20202065T1/hr unknown
2021
- 2021-03-08 CL CL2021000566A patent/CL2021000566A1/es unknown
- 2021-03-25 IL IL281807A patent/IL281807B2/en unknown
- 2021-05-25 JP JP2021087378A patent/JP7263439B2/ja active Active
- 2021-10-13 US US17/500,039 patent/US20220280496A1/en not_active Abandoned
2022
- 2022-11-16 AU AU2022271425A patent/AU2022271425B2/en active Active
2023
- 2023-04-12 JP JP2023064715A patent/JP2023089126A/ja active Pending
- 2023-05-08 US US18/313,428 patent/US20230301974A1/en not_active Abandoned
2024
- 2024-09-02 AU AU2024216533A patent/AU2024216533A1/en active Pending

Also Published As

Publication number	Publication date
MX2019012007A (es)	2019-11-11
SMT202100013T1 (it)	2021-03-15
EA201891642A1 (ru)	2019-08-30
IL242622A0 (en)	2016-02-01
TWI649306B (zh)	2019-02-01
TW202035370A (zh)	2020-10-01
AU2020267169A1 (en)	2020-12-03
US20160289243A1 (en)	2016-10-06
ES2851023T3 (es)	2021-09-02
AU2024216533A1 (en)	2024-09-19
US20160264526A1 (en)	2016-09-15
US20180092898A1 (en)	2018-04-05
SG11201509896VA (en)	2016-01-28
IL242622B (en)	2019-06-30
MY205257A (en)	2024-10-09
EA031254B1 (ru)	2018-12-28
PT3008039T (pt)	2021-01-13
IL281807A (en)	2021-05-31
US20230301974A1 (en)	2023-09-28
PH12015502705B1 (en)	2022-04-27
PH12020550916A1 (en)	2024-03-25
US20160287570A1 (en)	2016-10-06
US20160289190A1 (en)	2016-10-06
TN2015000521A1 (en)	2017-04-06
CA3200532A1 (en)	2014-12-18
MA53572A1 (fr)	2021-10-29
US9855259B2 (en)	2018-01-02
IL281807B2 (en)	2023-04-01
CR20210290A (es)	2021-07-23
HUE053047T2 (hu)	2021-06-28
US20140364455A1 (en)	2014-12-11
TW201922705A (zh)	2019-06-16
CN105358530A (zh)	2016-02-24
BR112015031004A2 (pt)	2020-05-12
CA2914723C (en)	2021-06-15
KR20160018576A (ko)	2016-02-17
MA38714A1 (fr)	2017-10-31
EP3008039A1 (en)	2016-04-20
NZ753956A (en)	2020-12-18
SG10201801402XA (en)	2018-04-27
KR20240159641A (ko)	2024-11-05
DK3008039T3 (da)	2021-01-04
JP2016528179A (ja)	2016-09-15
TWI698428B (zh)	2020-07-11
US20160289178A1 (en)	2016-10-06
JP2020147573A (ja)	2020-09-17
MX379872B (es)	2025-03-11
CN110003092A (zh)	2019-07-12
AU2014278428A1 (en)	2015-11-26
CR20160010A (es)	2016-02-04
CA2914723A1 (en)	2014-12-18
MA43288A1 (fr)	2020-04-30
PH12015502705A1 (en)	2016-03-14
JP7263439B2 (ja)	2023-04-24
CL2021000566A1 (es)	2021-09-03
CA3115609C (en)	2023-08-08
AU2018260844A1 (en)	2018-11-22
JOP20200296A1 (ar)	2017-06-16
CN110627708A (zh)	2019-12-31
AU2022271425B2 (en)	2024-06-13
US20220280496A1 (en)	2022-09-08
IL297860A (en)	2023-01-01
UY35605A (es)	2015-01-30
JO3768B1 (ar)	2021-01-31
AR119727A2 (es)	2022-01-05
AR096582A1 (es)	2016-01-20
EA201592305A1 (ru)	2016-05-31
JP2023089126A (ja)	2023-06-27
CA3115609A1 (en)	2014-12-18
EA202091612A1 (ru)	2020-10-05
US9757367B2 (en)	2017-09-12
MY194848A (en)	2022-12-19
UA121301C2 (uk)	2020-05-12
IL266504B (en)	2021-04-29
IL281807B (en)	2022-12-01
US9376386B2 (en)	2016-06-28
JP6891322B2 (ja)	2021-06-18
KR20210121270A (ko)	2021-10-07
PE20210153A1 (es)	2021-01-26
AU2018260844B2 (en)	2020-08-13
RS61192B1 (sr)	2021-01-29
TW201536743A (zh)	2015-10-01
IL266504A (en)	2019-07-31
JP6998655B2 (ja)	2022-02-04
US9801867B2 (en)	2017-10-31
CY1123661T1 (el)	2022-03-24
US20200281912A1 (en)	2020-09-10
AU2014278428B2 (en)	2018-11-15
JP2021130685A (ja)	2021-09-09
WO2014200937A1 (en)	2014-12-18
MA43288B1 (fr)	2020-10-28
EP3008039B1 (en)	2020-11-11
HRP20202065T1 (hr)	2021-02-19
KR20230019216A (ko)	2023-02-07
AU2020267169B2 (en)	2022-08-25
BR112015031004B1 (pt)	2022-09-20
PE20160113A1 (es)	2016-03-03
BR122020003153B1 (pt)	2022-09-27
EP3805232A1 (en)	2021-04-14
US9623018B2 (en)	2017-04-18
LT3008039T (lt)	2021-01-25
NZ714821A (en)	2020-10-30
CL2015003589A1 (es)	2016-06-17
MX2015016856A (es)	2016-04-07
CL2019000056A1 (es)	2019-05-03
AP2015008891A0 (en)	2015-11-30
TWI791153B (zh)	2023-02-01
AU2022271425A1 (en)	2022-12-22
CA3201958A1 (en)	2014-12-18
SI3008039T1 (sl)	2021-03-31

Publication	Publication Date	Title
CY2022018I2 (el)	2023-01-05	Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
PL3008039T3 (pl)	2021-04-19	Krystaliczna postać inhibitora mdm2
DK3080100T3 (da)	2023-02-06	Hæmmere af lysinspecifik demethylase-1
DK3027618T3 (da)	2020-10-12	Polymorf af syk-hæmmere
HK1221224A1 (zh)	2017-05-26	依洛昔巴特的結晶修飾物
LT3057586T (lt)	2020-03-10	Bromodomeno inhibitoriai
EP2969007A4 (en)	2016-07-27	HISTONE DEMETHYLASE INHIBITORS
HUE053815T2 (hu)	2021-07-28	SYK inhibitorok
AR095266A1 (es)	2015-09-30	Inhibidores de bromodominios tetraciclicos
HUE042443T2 (hu)	2019-06-28	GPR6 tetrahidropiridopirazin-modulátorai
SMT201700363T1 (it)	2017-09-07	Inibitori di bromodominio cristallini
EP2948458A4 (en)	2016-07-27	BTK INHIBITORS
DK2981255T3 (da)	2022-11-14	Terapeutiske anvendelser af empagliflozin
RS57039B1 (sr)	2018-05-31	Kristalni oblici inhibitora faktora xia
EP2948431A4 (en)	2016-10-26	BTK INHIBITORS
DK3068776T3 (da)	2019-07-29	Inhibitorer af replikation af influenzavira
LT3293176T (lt)	2021-03-25	Pde4 inhibitoriaus kristalinė forma
EP3632467C0 (en)	2023-09-27	COMPLEMENT FACTOR H INHIBITORS
EP2945942A4 (en)	2016-08-03	Voriconazole IMMUNOASSAY
EP2968275A4 (en)	2016-08-10	LXR MODULATORS
HK1222339A1 (zh)	2017-06-30	金屬-β-內酰胺酶的抑制劑
EP2858975A4 (en)	2015-12-09	FBXO3 INHIBITORS
DK2888228T3 (da)	2019-07-15	Inhibitorer af CD40-TRAF6 interaktion
EP2959896A4 (en)	2016-08-17	INHIBITOR OF PHOSPHORYLATION OF PROTEIN T
FR2997080B1 (fr)	2015-11-27	Inhibiteurs de neprilysine